Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 8/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | NCF1 | P14598 | 1/20 | 0.36 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30983466 | 0.89 | PIK3CD (0.41) | PIK3CD | |
| SCHEMBL30983519 | 0.89 | PIK3CD (0.41) | PIK3CD | |
| SCHEMBL30983778 | 0.88 | PIK3CD (0.42) | PIK3CD | |
| SCHEMBL30983437 | 0.87 | PIK3CD (0.40) | PIK3CD | |
| SCHEMBL30983527 | 0.85 | PIK3CD (0.41) | PIK3CD | |
| SCHEMBL31321975 | 0.85 | HTR6 (0.42) | HTR6SOS1PIK3CD | |
| SCHEMBL30983453 | 0.85 | PIK3CD (0.39) | HTR6SOS1PIK3CD | |
| SCHEMBL30983394 | 0.84 | PIK3CD (0.39) | HTR6SOS1PIK3CD | |
| SCHEMBL30983903 | 0.84 | PIK3CD (0.42) | CYP1A2PIK3CD | |
| SCHEMBL30983468 | 0.81 | CNR1 (0.40) | HTR6PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | claimed |
| WO-2024121753-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-13 | — | — | WO | claimed |
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| US-12414954-B2 | POLQ inhibitors | ASTRAZENECA AB (SE) | 2025-09-16 | — | — | US | disclosed |
| US-20250195530-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2025-06-19 | — | — | US | disclosed |
| US-20240366615-A1 | POLQ INHIBITORS | ASTRAZENECA UK LIMITED (GB) | 2024-11-07 | — | — | US | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024121753-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240366615-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | HTR6 4806/4885SOS1 4302/4885CYP1A2 1577/4885 |
| US-12414954-B2 | POLQ inhibitors | POLQ, POLG, POLB | HTR6 4806/4885SOS1 4302/4885CYP1A2 1577/4885 |
| US-20250195530-A1 | POLQ INHIBITORS | POLQ, POLG, POLB | HTR6 4806/4885SOS1 4302/4885CYP1A2 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.